Paris, France, April 25, 2013 – NANOBIOTIX (Euronext: NANO–ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its audited consolidated results for the 2012 fiscal year closed on December 31.
The 2012 sales recorded by NANOBIOTIX corresponds to the pro-rata share of the upfront payment received by the Company in August 2012, within the framework of the licensing contract signed with the Taiwanese company PharmaEngine for the development and marketing of NBTXR3 in the Asia-Pacific region. This upfront payment totaled €810,640. These sales are apportioned using the straight-line method between the date the contract was signed and the scheduled marketing launch in the region concerned. Therefore, the pro-rata amount for the period is €74,153. This figure is in line with the Company’s development plan, where the strategy is focused on the development of its NanoXray technology and the marketing of its lead product, NBTXR3.
Total revenue also includes subsidies and research tax credit. The decrease in total revenue is the result of the reduced research tax credit in 2012 due to the payment of a repayable advance from OSEO (thereby reducing the eligible costs basis) during the first half of 2012.
Spending was essentially associated with the development of NBTXR3, which is currently being tested in a phase I study at the Institut Gustave Roussy in patients with advanced Soft Tissue Sarcoma (STS). The publication of positive preliminary results regarding the safety of NBTXR3 in November 2012 was a very encouraging milestone in the clinical validation process. In the short term, the Company expects further results regarding the study progress.
Most of the expenses recorded by the company mainly correspond to the purchasing of services, subcontracting costs and personal charges. The core operating loss was -€5,152,827, a similar figure to that recorded in 2011. This level of operating loss is consistent with NANOBIOTIX’s strategy with, through its positioning on a state-of-the-art technological sector involving major clinical developments, negative operating cash flow since its creation.
The financial loss was -€99,180 which corresponded to interest on the bond issue and costs associated with the restatement of repayable advances. Combined with a tax burden of €78,889, the net loss was -€5,330,896.
Next financial press release: revenue for the 1st quarter of 2013 on May 15, 2013
About NANOBIOTIX: www.nanobiotix.com/fr
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy and brachytherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.
Nanobiotix is listed on the NYSE Euronext regulated market in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).
CEO and Co-founder
Tel: +33 (0)1 40 26 07 55
Financial communication and Investor relations
Louis-Victor Delouvrier /
Tel: +33 (0)1 44 71 98 53
Nadège Le Lezec
Tel: +33 (0)1 53 63 27 27